ViiV, Vertex Sue Over Mylan's Bid To Market Generic Lexiva

Law360, New York (August 24, 2012, 1:13 PM EDT) -- ViiV Healthcare Co. and Vertex Pharmaceuticals Inc. slapped Mylan Inc. with a patent infringement lawsuit in Delaware on Wednesday over Mylan's bid for U.S. regulatory approval to make and sell a generic version of the anti-HIV drug Lexiva.

North Carolina-based ViiV and Massachusetts-based Vertex said that Mylan infringed a patent owned by Vertex, and exclusively licensed to ViiV, when it submitted an abbreviated new drug application to the U.S. Food and Drug Administration seeking a green light for the manufacture, use and sale of generic fosamprenavir...
To view the full article, register now.